Cytek Biosciences Stock Analysis

Cytek Stock Analysis Notes

About 61.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.72. Some equities with similar Price to Book (P/B) outperform the market in the long run. Cytek Biosciences recorded a loss per share of 0.08. The entity had not issued any dividends in recent years. Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California. Cytek Biosciences operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 555 people. For more info on Cytek Biosciences please contact Wenbin Jiang at 877 922 9835 or go to https://cytekbio.com.

Cytek Biosciences Investment Alerts

Cytek Biosciences Upcoming and Recent Events

Cytek Largest EPS Surprises

View All Earnings Estimates

Cytek Biosciences Environmental, Social, and Governance (ESG) Scores

Cytek Biosciences Thematic Classifications

Cytek Stock Institutional Investors

Note, although Cytek Biosciences' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Cytek Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 660.8 M.

Cytek Profitablity

The company has Profit Margin (PM) of (0.05) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.08) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.08.

Management Efficiency

Cytek Biosciences has return on total asset (ROA) of (0.0274) % which means that it has lost $0.0274 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0254) %, meaning that it created substantial loss on money invested by shareholders. Cytek Biosciences' management efficiency ratios could be used to measure how well Cytek Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of February 26, 2025, Return On Tangible Assets is expected to decline to -0.03. The current year's Return On Capital Employed is expected to grow to -0.07. At present, Cytek Biosciences' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 123.6 M, whereas Total Assets are forecasted to decline to about 389 M.

Technical Drivers

As of the 26th of February, Cytek Biosciences shows the Standard Deviation of 4.03, mean deviation of 2.54, and Risk Adjusted Performance of (0.02). Cytek Biosciences technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

Cytek Biosciences Price Movement Analysis

Cytek Biosciences Insider Trading Activities

Cytek Biosciences Outstanding Bonds

Cytek Biosciences Predictive Daily Indicators

Cytek Biosciences Corporate Filings

Cytek Biosciences Forecast Models

Cytek Biosciences' time-series forecasting models are one of many Cytek Biosciences' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cytek Biosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Cytek Biosciences prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Cytek shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Cytek Biosciences. By using and applying Cytek Stock analysis, traders can create a robust methodology for identifying Cytek entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Cytek analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Cytek analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Cytek Biosciences stock analysis indicators help investors evaluate how Cytek Biosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Cytek Biosciences shares will generate the highest return on investment. By understating and applying Cytek Biosciences stock analysis, traders can identify Cytek Biosciences position entry and exit signals to maximize returns.

When running Cytek Biosciences' price analysis, check to measure Cytek Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytek Biosciences is operating at the current time. Most of Cytek Biosciences' value examination focuses on studying past and present price action to predict the probability of Cytek Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cytek Biosciences' price. Additionally, you may evaluate how the addition of Cytek Biosciences to your portfolios can decrease your overall portfolio volatility.